Top

Diagnostic Pathology

Published in:

Open Access 01-12-2014 | Research

Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein

Authors: Yan Wang, Qinglong Shang, Weizhen Xu, Di Li, Hongxi Gu, Lanlan Wei

Published in: Diagnostic Pathology | Issue 1/2014

Abstract

Background

Human papillomavirus type 16 (HPV16) infection is implicated in cervical carcinogenesis. This study aimed to characterize two new monoclonal antibodies (mAbs) against HPV L1 protein.

Methods

The immunocompetence of AE3 and AG7 mAbs for HPV L1 protein was evaluated by Western blot analysis, immunostaining, hemagglutination inhibition assay, and ELISA. The heavy chain variable region (VH) and light chain variable region (VL) of AE3 and AG7 mAbs were sequenced and analyzed.

Results

Both mAbs specifically recognized HPV16 L1 and virus-like particles (VLPs). Both the affinity and the titer of AE3 mAb were higher than that of AG7. There were differences in sequences in the complementary determining regions (CDR) 2 and 3 of VL, as well as in the CDR1 and CDR3 of VH. The two mAbs have distinct predicted three-dimensional structures.

Conclusions

We characterized two mAbs neutralizing antibodies for HPV L1 protein, which would help develop genetic-engineered neutralizing antibodies against HPV16 for diagnostic and therapeutic purposes.

De Vuyst H, Clifford G, Li N, Franceschi S: HPV infection in Europe. Eur J Cancer. 2009, 45: 2632-2639.PubMedCrossRef

Franceschi S: The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res. 2005, 166: 277-297.PubMedCrossRef

Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005, 14: 467-475.PubMedCrossRef

García-Espinosa B, Moro-Rodríguez E, Alvarez-Fernández E: Human papillomavirus genotypes in human immunodeficiency virus-positive patients with anal pathology in Madrid. Spain. Diagn Pathol. 2013, 8: 204-CrossRef

Frazer IH: Cervical cancer vaccine development. Sex Health. 2010, 7: 230-234.PubMedCrossRef

Luciani S, Jauregui B, Kieny C, Andrus JK: Human papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries. Immunotherapy. 2009, 1: 795-807.PubMedCrossRef

Carestiato FN, Silva KC, Balthazar DS, Silva L, Marinho M, Oliveira LH, Cavalcanti SM: Analysis of molecular biology techniques for the diagnosis of human papillomavirus infection and cervical cancer prevention. Rev Soc Bras Med Trop. 2006, 39: 428-432.PubMedCrossRef

Matsukura T, Sugase M: Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. Int J Gynecol Cancer. 2008, 18: 1042-1050.PubMedCrossRef

Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA: Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007, 25: 4324-4333.PubMedCrossRef

10.

Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Müller M, Pawlita M, Schäfer K, Sehr P, Staib C, Sutter G, Gissmann L: Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol. 2003, 77: 4635-4645.PubMedPubMedCentralCrossRef

11.

Schiller JT, Lowy DR: Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther. 2001, 1: 571-581.PubMedCrossRef

12.

Chen PP: Structural analyses of human developmentally regulated Vh3 genes. Scand J Immunol. 1990, 31: 257-267.PubMedCrossRef

13.

Wilson N, Simpson R, Cooper-Liddell C: Introductory glycosylation analysis using SDS-PAGE and peptide mass fingerprinting. Methods Mol Biol. 2009, 534: 205-212.PubMed

14.

Matoba N, Kajiura H, Cherni I, Doran JD, Bomsel M, Fujiyama K, Mor TS: Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR. Plant Biotechnol J. 2009, 7: 129-145.PubMedCrossRef

15.

Mageed RA, Harmer IJ, Wynn SL, Moyes SP, Maziak BB, Brüggemann M, MacKworth-Young CG: Rearrangement of the human heavy chain variable region gene V3-23 in transgenic mice generates antibodies reactive with a range of antigens on the basis of VHCDR3 and residues intrinsic to the heavy chain variable region. Clin Exp Immunol. 2001, 123: 1-8.PubMedPubMedCentralCrossRef

Title: Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein
Authors: Yan Wang
Qinglong Shang
Weizhen Xu
Di Li
Hongxi Gu
Lanlan Wei
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2014
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/1746-1596-9-101

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Association between miR-27a genetic variants and susceptibility to colorectal cancer

Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas

Deeply located low-grade fibromyxoid sarcoma with FUS-CREB3L2 gene fusion in a 5-year-old boy with review of literature

Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma

Bioinformatics analysis of Rab GDP dissociation inhibitor beta and its expression in non-small cell lung cancer

Erythrodermic psoriasis with bullous pemphigoid: combination treatment with methotrexate and compound glycyrrhizin